Most prominently we noted reduction in expression of the Hh pathway inhibitors GLI3 and SUFU (both p < 0.05; Fig. 1B) in CP-CML LSC compared to normal HSC. This evidence concerns the gene GLI3 and chronic myelogenous leukemia, BCR-ABL1 positive.